ACVR1 and fibrodysplasia ossificans progressiva: Since the CD14+ cells express ACVR-1 (19), we hypothesize that Activin-A interacts more strongly with FOP-patient derived CD14+ cells resulting in a stronger inhibition of osteoclast formation in FOP patients compared with the healthy controls.